A preliminary study of concurrent gains and losses across gene expression profiles and comparative genomic hybridization in Taiwanese breast cancer patients

Chi Cheng Huang, Jaan Yeh Jeng, Shih Hsin Tu, Heng Hui Lien, Ching Shui Huang, Liang Chuan Lai, Eric Y. Chuang

Research output: Contribution to journalArticle

Abstract

Purpose: The aim of the study was to perform genome-wide characterization of Taiwanese breast cancer at the molecular level by integrating 2 microarray technologies: comparative genomic hybridization (CGH) for analyzing DNA copy number changes, and gene expression profiles for determining transcriptional variations. Concurrent gains and losses from the same subject across genomic and transcriptional contexts may indicate potential biomarkers for endemic breast cancer. Methods: Fourteen pairs of cancerous and normal breast tissue were collected prospectively. Genomic DNA, messenger RNA, and corresponding normal controls were extracted from fresh frozen samples. Affymetrix U133 plus 2.0 and Agilent aCGH Human 105k microarrays were used for gene expression profiling and for detecting copy number variation. Concurrent gains and losses were declared if and only if significant changes in a coherent manner were observed for both gene expression and array CGH platforms within the same study subject. Results: Among the 14 breast cancer samples that were assayed, 7 were estrogen receptor (ER)-positive. The most common repeated concurrent gains (in 33% of the samples) were LAPTM4B, HRSP12, WISP1, SQLE, GINS4, LYZ, and DSCC1. For clinical ER status relevance, there were 294 concurrent gains and 133 concurrent losses, and these were reduced to 30 and 27 cytobands, respectively. Concurrent gains were more common among ER-negative tumors in 1p32, 1p34, 1q21-23, and 17q25, whereas for ER-positive tumors, a gain in 8p11 was reported. Concurrent losses were observed in 8p21 for ER-positive breast cancers. Conclusions: Breast cancer oncogenesis could originate from DNA copy number changes and persist through transcription in gene expression patterns. Genes with coherent patterns at both chromosomal and transcriptional levels are more likely to serve as potential biomarkers for sporadic breast cancer. In the current study, we identified several candidate genes specific for Taiwanese breast cancer, and their clinical implications deserve extensive evaluation with more samples in the future.

Original languageEnglish
Pages (from-to)18-24
Number of pages7
JournalTranslational Cancer Research
Volume2
Issue number1
DOIs
Publication statusPublished - Feb 1 2013

Fingerprint

Comparative Genomic Hybridization
Transcriptome
Cohort Studies
Breast Neoplasms
Estrogen Receptors
DNA Copy Number Variations
Biomarkers
Gene Expression
Gene Expression Profiling
Genes
Neoplasms
Carcinogenesis
Breast
Genome
Technology
Messenger RNA
DNA

Keywords

  • Breast cancer
  • Comparative genomic hybridization
  • Concurrent gains and losses
  • Gene expression
  • Taiwan

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

A preliminary study of concurrent gains and losses across gene expression profiles and comparative genomic hybridization in Taiwanese breast cancer patients. / Huang, Chi Cheng; Jeng, Jaan Yeh; Tu, Shih Hsin; Lien, Heng Hui; Huang, Ching Shui; Lai, Liang Chuan; Chuang, Eric Y.

In: Translational Cancer Research, Vol. 2, No. 1, 01.02.2013, p. 18-24.

Research output: Contribution to journalArticle

Huang, Chi Cheng ; Jeng, Jaan Yeh ; Tu, Shih Hsin ; Lien, Heng Hui ; Huang, Ching Shui ; Lai, Liang Chuan ; Chuang, Eric Y. / A preliminary study of concurrent gains and losses across gene expression profiles and comparative genomic hybridization in Taiwanese breast cancer patients. In: Translational Cancer Research. 2013 ; Vol. 2, No. 1. pp. 18-24.
@article{62eac50a347f4967aee769f592bff0af,
title = "A preliminary study of concurrent gains and losses across gene expression profiles and comparative genomic hybridization in Taiwanese breast cancer patients",
abstract = "Purpose: The aim of the study was to perform genome-wide characterization of Taiwanese breast cancer at the molecular level by integrating 2 microarray technologies: comparative genomic hybridization (CGH) for analyzing DNA copy number changes, and gene expression profiles for determining transcriptional variations. Concurrent gains and losses from the same subject across genomic and transcriptional contexts may indicate potential biomarkers for endemic breast cancer. Methods: Fourteen pairs of cancerous and normal breast tissue were collected prospectively. Genomic DNA, messenger RNA, and corresponding normal controls were extracted from fresh frozen samples. Affymetrix U133 plus 2.0 and Agilent aCGH Human 105k microarrays were used for gene expression profiling and for detecting copy number variation. Concurrent gains and losses were declared if and only if significant changes in a coherent manner were observed for both gene expression and array CGH platforms within the same study subject. Results: Among the 14 breast cancer samples that were assayed, 7 were estrogen receptor (ER)-positive. The most common repeated concurrent gains (in 33{\%} of the samples) were LAPTM4B, HRSP12, WISP1, SQLE, GINS4, LYZ, and DSCC1. For clinical ER status relevance, there were 294 concurrent gains and 133 concurrent losses, and these were reduced to 30 and 27 cytobands, respectively. Concurrent gains were more common among ER-negative tumors in 1p32, 1p34, 1q21-23, and 17q25, whereas for ER-positive tumors, a gain in 8p11 was reported. Concurrent losses were observed in 8p21 for ER-positive breast cancers. Conclusions: Breast cancer oncogenesis could originate from DNA copy number changes and persist through transcription in gene expression patterns. Genes with coherent patterns at both chromosomal and transcriptional levels are more likely to serve as potential biomarkers for sporadic breast cancer. In the current study, we identified several candidate genes specific for Taiwanese breast cancer, and their clinical implications deserve extensive evaluation with more samples in the future.",
keywords = "Breast cancer, Comparative genomic hybridization, Concurrent gains and losses, Gene expression, Taiwan",
author = "Huang, {Chi Cheng} and Jeng, {Jaan Yeh} and Tu, {Shih Hsin} and Lien, {Heng Hui} and Huang, {Ching Shui} and Lai, {Liang Chuan} and Chuang, {Eric Y.}",
year = "2013",
month = "2",
day = "1",
doi = "10.3978/j.issn.2218-676X.2013.02.07",
language = "English",
volume = "2",
pages = "18--24",
journal = "Translational Cancer Research",
issn = "2218-676X",
publisher = "AME Publishing Company",
number = "1",

}

TY - JOUR

T1 - A preliminary study of concurrent gains and losses across gene expression profiles and comparative genomic hybridization in Taiwanese breast cancer patients

AU - Huang, Chi Cheng

AU - Jeng, Jaan Yeh

AU - Tu, Shih Hsin

AU - Lien, Heng Hui

AU - Huang, Ching Shui

AU - Lai, Liang Chuan

AU - Chuang, Eric Y.

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Purpose: The aim of the study was to perform genome-wide characterization of Taiwanese breast cancer at the molecular level by integrating 2 microarray technologies: comparative genomic hybridization (CGH) for analyzing DNA copy number changes, and gene expression profiles for determining transcriptional variations. Concurrent gains and losses from the same subject across genomic and transcriptional contexts may indicate potential biomarkers for endemic breast cancer. Methods: Fourteen pairs of cancerous and normal breast tissue were collected prospectively. Genomic DNA, messenger RNA, and corresponding normal controls were extracted from fresh frozen samples. Affymetrix U133 plus 2.0 and Agilent aCGH Human 105k microarrays were used for gene expression profiling and for detecting copy number variation. Concurrent gains and losses were declared if and only if significant changes in a coherent manner were observed for both gene expression and array CGH platforms within the same study subject. Results: Among the 14 breast cancer samples that were assayed, 7 were estrogen receptor (ER)-positive. The most common repeated concurrent gains (in 33% of the samples) were LAPTM4B, HRSP12, WISP1, SQLE, GINS4, LYZ, and DSCC1. For clinical ER status relevance, there were 294 concurrent gains and 133 concurrent losses, and these were reduced to 30 and 27 cytobands, respectively. Concurrent gains were more common among ER-negative tumors in 1p32, 1p34, 1q21-23, and 17q25, whereas for ER-positive tumors, a gain in 8p11 was reported. Concurrent losses were observed in 8p21 for ER-positive breast cancers. Conclusions: Breast cancer oncogenesis could originate from DNA copy number changes and persist through transcription in gene expression patterns. Genes with coherent patterns at both chromosomal and transcriptional levels are more likely to serve as potential biomarkers for sporadic breast cancer. In the current study, we identified several candidate genes specific for Taiwanese breast cancer, and their clinical implications deserve extensive evaluation with more samples in the future.

AB - Purpose: The aim of the study was to perform genome-wide characterization of Taiwanese breast cancer at the molecular level by integrating 2 microarray technologies: comparative genomic hybridization (CGH) for analyzing DNA copy number changes, and gene expression profiles for determining transcriptional variations. Concurrent gains and losses from the same subject across genomic and transcriptional contexts may indicate potential biomarkers for endemic breast cancer. Methods: Fourteen pairs of cancerous and normal breast tissue were collected prospectively. Genomic DNA, messenger RNA, and corresponding normal controls were extracted from fresh frozen samples. Affymetrix U133 plus 2.0 and Agilent aCGH Human 105k microarrays were used for gene expression profiling and for detecting copy number variation. Concurrent gains and losses were declared if and only if significant changes in a coherent manner were observed for both gene expression and array CGH platforms within the same study subject. Results: Among the 14 breast cancer samples that were assayed, 7 were estrogen receptor (ER)-positive. The most common repeated concurrent gains (in 33% of the samples) were LAPTM4B, HRSP12, WISP1, SQLE, GINS4, LYZ, and DSCC1. For clinical ER status relevance, there were 294 concurrent gains and 133 concurrent losses, and these were reduced to 30 and 27 cytobands, respectively. Concurrent gains were more common among ER-negative tumors in 1p32, 1p34, 1q21-23, and 17q25, whereas for ER-positive tumors, a gain in 8p11 was reported. Concurrent losses were observed in 8p21 for ER-positive breast cancers. Conclusions: Breast cancer oncogenesis could originate from DNA copy number changes and persist through transcription in gene expression patterns. Genes with coherent patterns at both chromosomal and transcriptional levels are more likely to serve as potential biomarkers for sporadic breast cancer. In the current study, we identified several candidate genes specific for Taiwanese breast cancer, and their clinical implications deserve extensive evaluation with more samples in the future.

KW - Breast cancer

KW - Comparative genomic hybridization

KW - Concurrent gains and losses

KW - Gene expression

KW - Taiwan

UR - http://www.scopus.com/inward/record.url?scp=84962672884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962672884&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2218-676X.2013.02.07

DO - 10.3978/j.issn.2218-676X.2013.02.07

M3 - Article

AN - SCOPUS:84962672884

VL - 2

SP - 18

EP - 24

JO - Translational Cancer Research

JF - Translational Cancer Research

SN - 2218-676X

IS - 1

ER -